UniQure shares fell Thursday after the gene therapy company said its Huntington's disease drug hit more regulatory roadblocks. Shares of the Lexington, Mass., company fell 15% early Thursday, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback